Floatz logo

Tabelecleucel

Allogeneic Hematopoietic Cell Transplant

Pierre Fabre MedicamentCell therapyPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

74 Active assets in the Allogeneic Hematopoietic Cell Transplant cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
The First Affiliated Hospital of Soochow University
Phase 3BBB
Busulphan
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
FILGRASTIM
National Cancer Institute (NCI)
Phase 2/3BBB
Decitabine
Chinese PLA General Hospital
Phase 4BBB
Cyclophosphamide
St. Jude Children's Research Hospital
Phase 3BBB

View all 50 →

Same molecule, other indications

Tabelecleucel is also rated in:

Solid Organ Transplant ComplicationsDormant
BB
Indicative ·
66 / 100
View asset →
Epstein-Barr virus-associated lymphoproliferative disorderDormant
BB
Indicative ·
66 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →